DLF: Bullish Momentum, Potential for Rally to ₹550-560 by Year-End, with Strong Support at ₹440-430 Zone. Consider ₹445 Accumulation, Manage Risk with Stop-Loss at ₹405, Exit Target at ₹710 or Beyond. Zomato: Zomato Share Price Sees Bullish Reversal, Eyes Potential Rally to ₹115 and Beyond. Consider…

Technical Analysis: DLF, Zomato and Dr. Lal PathLabs

Dr Lal PathLabs Ltd’s share price rose 0.68% after it reported 43.6% increase in profit for Q1 FY24. Revenues were up 7.76% to ₹541 crore. EBITDA rose 24.4% YoY to ₹146 crore. Intense competition in Delhi NCR may limit earnings growth. Stock downgraded to sell with revised target price of ₹2,110.

“Dr Lal PathLabs Ltd’s Share Price Rises 0.68% After 43.6% Increase in Profit for Q2 2023”

In today’s edition of Moneycontrol Pro Panorama: India’s drug regulation process needs overhaul, price hikes effect Dr Lal PathLabs’ performance, no push to the climate agenda at G20 summit, and more

Moneycontrol Pro Panorama | Even in a weakened state, China’s overhang over metals to continue

Revenues came in line with 7.6% YoY growth (9.7% non-Covid growth); sample growth of 6% but little by way of volumes.

Dr. Lal Pathlabs Q1 Results Review - Lack Of Volume Precludes Constructive Stance: Yes Securities

#DrLalPathLabs' June quarter profit beats estimates as it surged 43% year-on-year.

In conversation with CEO Bharath Uppiliappan on the company's growth roadmap. #BQLive 
--------------------------------------------------------------------------------------------------------------------
For more videos subscribe to our channel: http://bit.ly/32JXa74
Visit BQ Prime for more news: https://www.bqprime.com/
Don't enter the stock market unaware. Read all Research Reports here: https://www.bqprime.com/research-reports

For the latest business news and analysis
Subscribe to our Newsletters here: https://www.bqprime.com/my-bq/newsletter
Subscribe to our Telegram channel: https://t.me/BQPrime

Follow BQ Prime here
Twitter: https://twitter.com/bqprime
Facebook: https://www.facebook.com/BQPrime/
LinkedIn: https://www.linkedin.com/company/13184554/
Instagram: https://www.instagram.com/bqprime/
Pinterest: https://in.pinterest.com/BQPrimeNews/

Q1 Review: Dr Lal PathLabs' CEO On Earnings & Outlook For Upcoming Quarters | BQ Prime

Dr Lal PathLabs’ Q1 revenue rose 8% to Rs 541 crore as against an estimate of Rs 548 crore.

Dr Lal PathLabs Q1 Results: Profit Rises 43%, Beats Estimates

Here are the estimates of the major companies that are scheduled to announce their results on Thursday.

Nestle India, Indian Hotels, ACC, Dr Lal Pathlabs Q1 Results Today — Earnings Estimates

[PARTNERED]

Shashi Ranjan, Head, Customer Experience at Dr Lal PathLabs talks about how Generative AI can be used to understand customer needs and offer personalized services to patients in the healthcare industry at the Mint Future Ready - Lead the AI Era, sponsored by Microsoft. To know more about how Generative prompts productivity, imagination and innovation in the enterprise, read this Forrester trends with the Microsoft point of view at https://aka.ms/GenAI

Shashi Ranjan of Dr Lal PathLabs, at Mint Future Ready - Lead the AI Era, Gurugram

The companies themselves are trading at a higher valuation of 57 times FY24 earnings for Dr Lal PathLabs, 47 times, and 29 times for Metropolis and Thyrocare respectively

Dr Lal PathLabs, Metropolis and Thyrocare: Why shares underperformed last year and should you buy now?

As many as 88 stocks were on the short-covering list based on the open interest percentage. These included Rain Industries, Hindustan Aeronautics, Dr Lal PathLabs, LIC Housing Finance and Mahanagar Gas

Trade setup for Tuesday: Top 15 things to know before the opening bell

Om Manchanda, MD, Dr Lal PathLabs, speaks on the price hike expectations and FY24 business outlook. 'New entrants have led to heavy discounting in the industry', he said. 

'Large part of growth will come from tier-2 & tier-3 towns', he added. 

#drlalpathlabs #pricehikes #businessoutlook #FY24outlook #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday 

About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. 

You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/

You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.cnbctv18.com/minis/

Subscribe to our Channel: https://bit.ly/3nvEcxf

Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News
Follow us on Instagram: https://www.instagram.com/cnbctv18india/
Catch us on: Linkedin: https://in.linkedin.com/company/cnbc-tv18
n18oc_business

New Entrants Have Led To Heavy Discounting In The Industry: Dr Lal PathLabs' Om Manchanda

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator. 